司来吉兰与左旋多巴联用治疗帕金森病运动障碍的临床观察  

Clinical observation of Selegiline in combination with L-dopa on patients with parkinson movement disorders

作　　者：叶虹[1] 罗丽霞[1] 李飞[1] 刘清阁[1] 

机构地区：[1]南方医科大学附属南海人民医院神经内科,广东佛山528200

出　　处：《中国医药导报》2014年第28期58-61,共4页China Medical Herald

基　　金：广东省佛山市卫生局医学科研立项(编号2014226)

摘　　要：目的研究司来吉兰与左旋多巴二者联用治疗帕金森病运动障碍的临床效果和安全性。方法选择南方医科大学附属南海人民医院108例患者作为研究对象,所有患者均符合全国锥体外系疾病研讨会制订的帕金森诊断标准,且均排除家族性和老年性震颤等其他疾病,将其分为对照组和实验组各54例,两组患者在病情、年龄及性别等一般资料上具有可比性。对两组患者给予相同的静脉滴注10%葡萄糖溶液基础治疗,对照组在此基础上给予左旋多巴片3片/d和盐酸普拉克索片1片/d;实验组在应用左旋多巴的基础上,给予盐酸司来吉兰片1次/d,早餐后1 h服用,前2周的剂量为0.5 mg/次,第3周后增至1 mg/次。两组患者整个疗程均为8周。期间分别观察并记录两组患者治疗前后临床症状改善情况以及不良反应发生情况,以评价临床疗效。计算两组患者治疗前后的帕金森综合评分量表UPDRS得分。所得数据应用SPSS 17.0软件进行统计分析。结果治疗前,两组患者的UPDRS评分差异无统计学意义(P>0.05),治疗后,两组患者的UPDRS评分均较治疗前显著下降,差异有统计学意义(P<0.05);治疗2、4、8周后,实验组UPDRS评分下降程度均对照组明显(P<0.05);治疗8周后,实验组和对照组治疗总有效率分别为75.9%和40.7%,实验组显著优于对照组,差异有统计学意义(P<0.05);两组均无严重不良反应出现。结论采用司来吉兰联合左旋多巴治疗帕金森病运动障碍患者,治疗效果良好,临床症状改善情况理想,且安全性较高,值得在临床用药方案上进一步推荐使用。Objective To explore the clinical effect and safety of Selegiline in combination with L-dopa on Parkinson movement disorders therapy. Methods 108 patients in the Affiliated Nanhai People＇s Hospital of Southern Medical U- niversity were chosen as the research object, all the patients were in accordance with the national seminar for extrapyramidal disease diagnostic criteria of Parkinson＇s, and ruled out other diseases such as familial and senile tremor, they were divided into control group and experiment group with 54 cases in each group, two groups of patients in the general data, such as the illness, age and gender were comparable. Two groups of patients were given the same intravenous drip based treatment of 10% glucose solution. While the control group on the basis of the above were given L-dopa 3 pills/d and Pramipexole Hydrochloride 1 piece/d; the experiment group on the basis of the application of L- dopa were given Pramipexole Hydrochloride 1 time/d, 1 h after the breakfast, with the dose of 0.5 rag/time in the first two weeks, and 1 rag/time since the third week. The whole course of the treatment were 8 weeks for the two groups. Clinical symptoms improving and adverse reactions occurence were observed and recorded before and after treatment in the two groups, the clinical curative effect was evaluated. UPDRS score of two groups before and after treatment were observed, SPSS 17.0 software was used for statistical analysis. Results There was no significant difference of UPDRS between two groups before the treatment （P 〈0.05）. After the treatment, the UPDRS scores of control group and experiment group decreased （P 〈0.05）. Respectively, after 2, 4, 8 weeks＇treatment, UPDRS scores of experiment group hadsignificantly changed compared with those of control group （P 〈0.05）. After 8 weeks＇treatment, the effective rate of experiment group was 75.9%, while that of control group was 40.7%, the effect of experiment group was better than that of the control group with significant difference �

关 键 词：司来吉兰 左旋多巴 帕金森运动障碍 临床观察 

分 类 号：R971.5[医药卫生—药品]